Venus Remedies Limited (VENUSREM) - Net Assets

Latest as of September 2025: Rs5.94 Billion INR ≈ $64.27 Million USD

Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has net assets worth Rs5.94 Billion INR (≈ $64.27 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs7.68 Billion ≈ $83.07 Million USD) and total liabilities (Rs1.74 Billion ≈ $18.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Venus Remedies Limited (VENUSREM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs5.94 Billion
% of Total Assets	77.37%
Annual Growth Rate	16.29%
5-Year Change	40.14%
10-Year Change	28.18%
Growth Volatility	24.05

Venus Remedies Limited - Net Assets Trend (2006–2025)

This chart illustrates how Venus Remedies Limited's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Venus Remedies Limited for the complete picture of this company's asset base.

Annual Net Assets for Venus Remedies Limited (2006–2025)

The table below shows the annual net assets of Venus Remedies Limited from 2006 to 2025. For live valuation and market cap data, see Venus Remedies Limited market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs5.61 Billion ≈ $60.66 Million	+15.05%
2024-03-31	Rs4.88 Billion ≈ $52.73 Million	+5.91%
2023-03-31	Rs4.60 Billion ≈ $49.78 Million	+4.52%
2022-03-31	Rs4.40 Billion ≈ $47.63 Million	+10.03%
2021-03-31	Rs4.00 Billion ≈ $43.29 Million	+23.79%
2020-03-31	Rs3.23 Billion ≈ $34.97 Million	-2.75%
2019-03-31	Rs3.33 Billion ≈ $35.96 Million	-8.12%
2018-03-31	Rs3.62 Billion ≈ $39.14 Million	-19.86%
2017-03-31	Rs4.52 Billion ≈ $48.84 Million	+3.19%
2016-03-31	Rs4.38 Billion ≈ $47.33 Million	-4.17%
2015-03-31	Rs4.57 Billion ≈ $49.39 Million	-1.07%
2014-03-31	Rs4.62 Billion ≈ $49.92 Million	+21.76%
2013-03-31	Rs3.79 Billion ≈ $41.00 Million	+23.38%
2012-03-31	Rs3.07 Billion ≈ $33.23 Million	+29.70%
2011-03-31	Rs2.37 Billion ≈ $25.62 Million	+38.40%
2010-03-31	Rs1.71 Billion ≈ $18.51 Million	+23.51%
2009-03-31	Rs1.39 Billion ≈ $14.99 Million	+55.75%
2008-03-31	Rs889.86 Million ≈ $9.62 Million	+61.41%
2007-03-31	Rs551.31 Million ≈ $5.96 Million	+72.85%
2006-03-31	Rs318.96 Million ≈ $3.45 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Venus Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 215266100000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs2.15 Billion	38.38%
Common Stock	Rs133.70 Million	2.38%
Other Comprehensive Income	Rs2.44 Billion	43.50%
Other Components	Rs883.26 Million	15.75%
Total Equity	Rs5.61 Billion	100.00%

Venus Remedies Limited Competitors by Market Cap

The table below lists competitors of Venus Remedies Limited ranked by their market capitalization.

Company	Market Cap
Syrah Resources Ltd AU:SYR	$139.88 Million
Heidelberg Pharma AG F:HPHA	$139.89 Million
Multitude SE LSE:0R4W	$139.98 Million
UBcare. Co. Ltd KQ:032620	$140.04 Million
Laxmi Goldorna House Ltd NSE:LGHL	$139.82 Million
USBC, Inc. NYSE MKT:USBC	$139.73 Million
ANDREW PELLER LTD A F:ANJ	$139.73 Million
Samick Thk KO:004380	$139.72 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Venus Remedies Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,875,501,000 to 5,609,500,000, a change of 733,999,000 (15.1%).
Net income of 453,200,000 contributed positively to equity growth.
Other comprehensive income increased equity by 285,648,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs453.20 Million	+8.08%
Other Comprehensive Income	Rs285.65 Million	+5.09%
Other Changes	Rs-4.85 Million	-0.09%
Total Change	Rs-	15.05%

Book Value vs Market Value Analysis

This analysis compares Venus Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.31x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 25.50x to 2.31x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs37.94	Rs967.40	x
2007-03-31	Rs65.58	Rs967.40	x
2008-03-31	Rs105.27	Rs967.40	x
2009-03-31	Rs163.96	Rs967.40	x
2010-03-31	Rs202.03	Rs967.40	x
2011-03-31	Rs259.52	Rs967.40	x
2012-03-31	Rs334.34	Rs967.40	x
2013-03-31	Rs388.99	Rs967.40	x
2014-03-31	Rs410.44	Rs967.40	x
2015-03-31	Rs399.10	Rs967.40	x
2016-03-31	Rs381.26	Rs967.40	x
2017-03-31	Rs393.42	Rs967.40	x
2018-03-31	Rs293.26	Rs967.40	x
2019-03-31	Rs269.47	Rs967.40	x
2020-03-31	Rs262.01	Rs967.40	x
2021-03-31	Rs324.33	Rs967.40	x
2022-03-31	Rs329.50	Rs967.40	x
2023-03-31	Rs344.39	Rs967.40	x
2024-03-31	Rs364.74	Rs967.40	x
2025-03-31	Rs419.57	Rs967.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Venus Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.08%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.00%
• Asset Turnover: 0.91x
• Equity Multiplier: 1.28x
Recent ROE (8.08%) is below the historical average (14.16%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	50.69%	19.07%	1.36x	1.95x	Rs129.77 Million
2007	46.04%	17.33%	0.94x	2.82x	Rs198.70 Million
2008	40.24%	16.40%	1.05x	2.34x	Rs269.11 Million
2009	31.71%	16.31%	0.91x	2.14x	Rs300.92 Million
2010	23.11%	12.57%	0.90x	2.05x	Rs224.41 Million
2011	19.51%	12.69%	0.79x	1.95x	Rs225.26 Million
2012	15.32%	11.49%	0.71x	1.87x	Rs163.48 Million
2013	15.12%	12.25%	0.65x	1.89x	Rs193.97 Million
2014	13.93%	11.99%	0.64x	1.81x	Rs181.36 Million
2015	1.13%	1.11%	0.55x	1.84x	Rs-405.08 Million
2016	0.39%	0.41%	0.49x	1.93x	Rs-420.64 Million
2017	1.75%	2.00%	0.48x	1.84x	Rs-372.51 Million
2018	-8.48%	-8.31%	0.49x	2.07x	Rs-668.83 Million
2019	-8.59%	-9.00%	0.43x	2.20x	Rs-618.27 Million
2020	-3.09%	-2.97%	0.53x	1.97x	Rs-423.36 Million
2021	15.43%	11.27%	0.99x	1.39x	Rs217.37 Million
2022	9.25%	6.80%	1.03x	1.32x	Rs-33.20 Million
2023	5.77%	4.78%	0.92x	1.31x	Rs-194.64 Million
2024	5.84%	4.82%	0.94x	1.29x	Rs-202.64 Million
2025	8.08%	7.00%	0.91x	1.28x	Rs-107.75 Million

Industry Comparison

This section compares Venus Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $23,713,303,062
Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Venus Remedies Limited (VENUSREM)	Rs5.94 Billion	50.69%	0.29x	$139.85 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$988.60 Million	6.59%	1.36x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$6.52 Billion	21.67%	1.42x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$19.90 Billion	13.69%	0.46x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$1.16 Billion	12.69%	1.32x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.46 Billion	16.82%	0.29x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$8.73 Billion

About Venus Remedies Limited

NSE:VENUSREM India Drug Manufacturers - Specialty & Generic

Market Cap

$139.85 Million

Rs12.93 Billion INR

Market Cap Rank

#17891 Global

#932 in India

Share Price

Rs967.40

Change (1 day)

+3.65%

52-Week Range

Rs299.20 - Rs1069.05

All Time High

Rs1069.05